Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?
about
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaAntimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conferenceRisk Factors for and Outcomes of Bacteremia Caused by Extended-Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiella Species at a Canadian Tertiary Care Hospital.Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremiaAccess to antibiotics: a safety and equity challenge for the next decade.Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.New antibiotics for bad bugs: where are we?Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Treatment of multidrug-resistant Gram-negative infections in children.β-lactam/β-lactamase inhibitor combinations: from then to now.The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae.Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.[Antibiotic Stewardship 2.0 : Individualization of therapy].Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-LactamasesActivity of Ceftolozane-Tazobactam Tested against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States During 2013 to 2015.[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.Antimicrobial resistance in from healthy broilers in Egypt: emergence of colistin-resistant and extended-spectrum β-lactamase-producing
P2860
Q24601746-E282A32C-8D5C-4266-A1CF-D1C14094AF18Q26739860-90D78AD4-4867-4CF0-8C1B-858E1791ABE7Q33640559-F4D9B59A-1A11-4BBC-847B-F8C4A922D6BBQ35551647-87159489-BA31-4DEB-B4B3-AA31B21F6314Q35552650-A90C2114-66D9-40BB-B505-91F20EE13ADDQ35715650-30309B46-55AF-4354-B4DB-52EE3081D638Q36689032-646C1CB8-7A53-4D45-B50C-2A431D3B3664Q36969726-EC961144-FF57-44E4-B41E-1C0681FA356BQ38132217-62B2B0D3-5BBC-4220-AAAA-BF0520A88C8EQ38165138-E2AABB25-58A3-4738-AFB8-6C3F9CEB2783Q38185648-D11171E4-58A0-4912-BC12-649EDF4319E8Q38264182-A56FEAF2-5981-4084-99DF-EB3AB11D4A0DQ38497797-0AD28A3C-8A4F-44AC-8F3C-C1650DE2A061Q38739545-AA2484EC-B6AE-4523-BDFA-5EA46C6C0ED2Q38792841-3737D5B2-A0C5-4A2D-9BF1-220031391D26Q40176582-6DD307DD-81D7-400C-B294-5C6B469B6908Q40212000-B0C0CC5E-E64D-4A6D-83AB-53954071FC2FQ41217004-A57B5C01-71A3-47B3-B959-13C95F9CC895Q42358846-D849163F-B5F2-4CB8-BB6D-9D548EDCDC90Q47675324-16DF193D-6C97-400C-939F-FDA16FB534B0Q49589601-E516026D-59F2-40F6-BB24-AE96BA861924Q52695014-9BE064AD-4CE9-4324-99F1-17476CD526A8Q54333207-E141C3FB-B1CB-4A55-8816-664514BF208CQ58447916-C4AEAC4A-A7C8-4B62-AF3E-209D9D3E1380
P2860
Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@en
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@nl
type
label
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@en
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@nl
prefLabel
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@en
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@nl
P356
P1476
Can we really use ß-lactam/ß-l ...... -lactamase-producing bacteria?
@en
P2093
Federico Perez
P304
P356
10.1093/CID/CIR793
P407
P577
2011-11-04T00:00:00Z